Technical Analysis for CATB - Catabasis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 4.67 -2.91% -0.14
CATB closed down 2.91 percent on Friday, October 18, 2019, on 1.33 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CATB trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Calm After Storm Range Contraction -2.91%
NR7 Range Contraction -2.91%
Doji - Bullish? Reversal -2.91%
Calm After Storm Range Contraction -1.89%
Wide Bands Range Expansion -1.89%
Down 3 Days in a Row Weakness -1.89%
Down 4 Days in a Row Weakness -1.89%

Older signals for CATB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Catabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company's product development pipeline includes three clinical-stage product candidates, namely, CAT-1004, CAT-2000 series, including CAT-2054 and CAT-2003, and CAT-4001, and various programs in preclinical development.
Biopharmaceutical Diseases Lipid Disorders Cat
Is CATB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.76
52 Week Low 3.6
Average Volume 83,360
200-Day Moving Average 6.5139
50-Day Moving Average 5.7889
20-Day Moving Average 5.024
10-Day Moving Average 4.875
Average True Range 0.4365
ADX 22.67
+DI 14.3205
-DI 19.7644
Chandelier Exit (Long, 3 ATRs ) 5.0305
Chandelier Exit (Short, 3 ATRs ) 5.7295
Upper Bollinger Band 5.5914
Lower Bollinger Band 4.4566
Percent B (%b) 0.19
BandWidth 22.58758
MACD Line -0.3068
MACD Signal Line -0.3236
MACD Histogram 0.0168
Fundamentals Value
Market Cap 104.99 Million
Num Shares 22.5 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -2.73
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.02
Resistance 3 (R3) 5.05 4.96 4.96
Resistance 2 (R2) 4.96 4.88 4.95 4.94
Resistance 1 (R1) 4.82 4.82 4.78 4.79 4.92
Pivot Point 4.73 4.73 4.71 4.72 4.73
Support 1 (S1) 4.59 4.65 4.55 4.56 4.42
Support 2 (S2) 4.50 4.59 4.49 4.40
Support 3 (S3) 4.36 4.50 4.38
Support 4 (S4) 4.33